Vection Technologies has reported a milestone positive net cash flow in its traditionally weak quarter, driven by a 60% half-on-half revenue surge and strategic acquisition integration.
Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.